233 results on '"Malucchi, Simona"'
Search Results
2. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose
3. Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study
4. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions
5. Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
6. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study
7. Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study
8. Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report
9. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders
10. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study
11. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
12. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
13. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients
14. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study
15. “Better explanations” in multiple sclerosis diagnostic workup: A 3-year longitudinal study
16. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients
17. High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
18. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
19. Clinical Aspects of Immunogenicity to Biopharmaceuticals
20. Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers
21. Applicability of sNFL in Multiple Sclerosis as Additional Measure to Monitor Treatments in Clinical Practice and Implications in NEDA-3 Evaluation (S19.001)
22. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
23. Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α Therapy
24. Riproducibilità del punteggio EDSS calcolato con un nuovo software dedicato rispetto al metodo tradizionale in uso
25. Successful pregnancy and disease outcomes in a NMOSD patient treated with tocilizumab
26. Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group
27. Italian multicenter observational study on real-life experience with alemtuzumab in naïve patients with aggressive multiple sclerosis
28. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis
29. Prevalence and Significant Determinants of Post-traumatic Stress Disorder in a Large Sample of Patients with Multiple Sclerosis
30. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy
31. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
32. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients
33. Anti-interferon-β neutralising activity is not entirely mediated by antibodies
34. Comparison of three PCR assays for the evaluation of interferon-β biological activity in patients with multiple sclerosis
35. Loss of Braking Signals During Inflammation: A Factor Affecting the Development and Disease Course of Multiple Sclerosis
36. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)
37. Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients
38. Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis
39. MSJ872889_supplemental_table – Supplemental material for Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience
40. Neutralizing antibodies against IFN-β in multiple sclerosis: antagonization of IFN-β mediated suppression of MMPs
41. Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group
42. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience
43. Peg-Interferon beta 1a induces a sustained and long lasting overexpression of interferon related genes. (P3.2-073)
44. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.
45. Neutralizing antibodies against IFN‐β in multiple sclerosis: antagonization of IFN‐β mediated suppression of MMPs
46. Efficacy and Safety of Alemtuzumab in Real World Italian Patients Switching from Natalizumab (P6.357)
47. Clinical Characteristics of MOG and AQP associated Neuromyelitis Optica Spectrum Disorder (NMOSD) in Adults (S13.002)
48. The Effectiveness of a Body-Affective Mindfulness Intervention for Multiple Sclerosis Patients with Depressive Symptoms: A Randomized Controlled Clinical Trial
49. High risk PML patients switching from natalizumab to alemtuzumab (P2.407)
50. High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.